ARDX - Ardelyx, Inc.

NasdaqGM - NasdaqGM Real Time Price. Currency in USD

Ardelyx, Inc.

34175 Ardenwood Boulevard
Suite 200
Fremont, CA 94555
United States

Full Time Employees86

Key Executives

NameTitlePayExercisedYear Born
Mr. Michael G. RaabPres, CEO & Director780.56kN/A1965
Ms. Elizabeth A. GrammerExec. VP, Gen. Counsel, Sec. & Head of HR504kN/A1964
Mr. David RosenbaumChief Devel. Officer521.64kN/A1961
Mr. Mark E. KaufmannCFO & TreasurerN/AN/A1968
Mr. Jeffrey W. JacobsSr. VP of Technical OperationsN/AN/A1963
Amounts are as of December 31, 2018 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.


Ardelyx, Inc., a specialized biopharmaceutical company, develops and sells medicines for the treatment of cardio renal diseases in the United States and internationally. The company's lead product candidate is tenapanor, which has completed Phase III clinical trial for the treatment of patients with irritable bowel syndrome with constipation, as well as in Phase III clinical trial for the treatment of hyperphosphatemia in end-stage renal disease patients on dialysis. It also develops RDX013, a small molecule potassium secretagogue program for the treatment of patients with hyperkalemia. The company was formerly known as Nteryx, Inc. and changed its name to Ardelyx, Inc. in June 2008. Ardelyx, Inc. was founded in 2007 and is headquartered in Fremont, California.

Corporate Governance

Ardelyx, Inc.’s ISS Governance QualityScore as of October 4, 2019 is 9. The pillar scores are Audit: 2; Board: 9; Shareholder Rights: 8; Compensation: 9.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.